Introduction {#s1}
============

Crohn's disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD), are characterized by chronic relapsing inflammation of the gastrointestinal tract ([@bib55]; [@bib72]). The etiology of IBD is complex, as host genetics, the gut microbiota and environmental exposures all contribute to disease pathogenesis ([@bib74]; [@bib18]). A breakdown in the ability of a genetically susceptible host to respond appropriately to the gut microbiota may lead to an overactive local immune response ([@bib65]; [@bib13]) initiating the chronic cycle of intestinal inflammation core to IBD. Many genes within IBD loci are directly involved in pathways controlling the sensing and innate responses to bacteria ([@bib74]; [@bib29]). The relatively longstanding observation that there is an absence of intestinal inflammation in several gnotobiotic mouse models of spontaneous colitis maintained under germ-free housing conditions supports this idea ([@bib14]; [@bib66]). Furthermore, data from IBD patients demonstrating that diversion of the fecal stream greatly improves symptoms ([@bib62]; [@bib46]) as well as reduces inflammatory cytokine levels ([@bib10]) also lends plausibility to this concept.

Dysbiosis of the gut microbiota, including alterations in frequency, diversity and richness of microbial populations ([@bib44]; [@bib51]), has been associated with IBD ([@bib47]; [@bib16]; [@bib73]). For example, a reduction in the abundance of the phylum Firmicutes, including the genus *Clostridium* ([@bib56]) as well as Proteobacteria and Actinobacteria, has been associated with IBD ([@bib16]). In contrast, there is variation in the abundance of *Bacteroides* in IBD ([@bib67]; [@bib68]; [@bib20]; [@bib58]; [@bib7]), including an increase in *Bacteroides fragilis* ([@bib68]; [@bib20]). Additionally, certain microbes, including *Ruminococcus gnavus*, are able to thrive in the high levels of oxidative stress in the inflamed gut and are associated with increased disease activity ([@bib22]). A population-based metagenomics analysis found associations between fecal levels of secreted proteins and microbiome composition ([@bib77]). Additionally, the unique ileal transcriptome of CD patients is associated with alterations in Firmicutes ([@bib21]), implicating a role for genetics in shaping the microbiota. Genome wide association studies have shown that host genetic variants play a role in microbial dysbiosis ([@bib23]). Further supporting the idea that these microbial alterations could be the driving force behind the immune response, microbial changes have been observed prior to onset of disease symptoms and specific microbiota signatures are associated with disease location ([@bib27]). While data suggest a dynamic interplay between the microbiota, the immune system and disease pathophysiology ([@bib52]), how dysbiosis manifests and more specifically how individual species are affected by host genetics is less well understood. Because there is substantial diversity in disease location, symptoms and genetic susceptibility in IBD, understanding how specific microbial alterations occur will be important for identifying disease subtypes as well as developing precision medicine treatment options. Genetic diversity among patients is a compounding factor with respect to disease phenotype, suggesting that specific risk loci may play a role in underlying microbial community makeup.

Genome-wide association studies have linked over 230 genetic risk loci to increased IBD risk ([@bib29]; [@bib41]; [@bib12]; [@bib43]). The microbiota and disease severity have also been linked to genetic risk ([@bib49]). Genetics can affect the composition of the human gut microbiome ([@bib23]). Additionally, IBD is associated with a variety of risk alleles that affect immune activation in response to microbial recognition and handling ([@bib11]). Many studies have linked IBD to genetic risk variants in *NOD2* ([@bib72]), which is involved in recognition of bacterial muramyl dipeptide, but one study has linked the presence of multiple NOD2 variants to increased levels of *Enterobacteriaceae* ([@bib33]). A single nucleotide polymorphism (SNP) in *ATG16L1* (re2241880, Thr300Ala) is associated with an increased risk of CD ([@bib24]; [@bib59]). ATG16L1 functions in autophagy, a cellular recycling system that aids in the sequestration of intracellular bacteria ([@bib9]; [@bib70]). *ATG16L1* hypomorphic mice have defects in anti-microbial peptide secretion by Paneth cells ([@bib5]) and *ATG16L1*-deficient macrophages show increased secretion of pro-inflammatory cytokines ([@bib63]). Conditional deletion of *ATG16L1* specifically in epithelial cells reduces autophagy and renders mice more susceptible to *Salmonella enterica* serovar Typhimurium infection and systemic translocation ([@bib8]). The Thr300Ala (T300A) variant displays enhanced degradation via active caspase 3 resulting in a reduction in the levels of ATG16L1 protein and reduced levels of autophagic flux ([@bib50]; [@bib39]). Moreover, microbial signatures are associated with variants in the gene for NOD2 ([@bib74]), which interacts with ATG16L1 ([@bib65]). T300A knock-in mice display defects in Paneth cells and goblet cells ([@bib39]). More recently, T300A has been shown to directly affect lysozyme secretion from Paneth cells in mice in the context of infection ([@bib3]). These data suggest that T300A may play a role in shaping the response to gut microbes. Specifically, this may occur by loss of autophagy due to enhanced degradation of ATG16L1 T300A and altered anti-microbial peptide secretion. These effects in turn may affect microbial composition. While many of these studies have observed differences in mice in the context of infection, the effect of T300A on microbial composition has not been addressed. Furthermore, while these data suggest that alterations in the makeup of gut microbial communities may arise from the presence of certain risk alleles and may shape the downstream immune response; this has yet to be formally demonstrated.

A dysfunctional response to the microbiota can lead to adaptive immune cell infiltration in the gut during colitis ([@bib15]; [@bib42]) and is a key contributor to disease pathology. Initially, studies suggested a role for Th1 cells in CD ([@bib54]) whereas Th2 cells were viewed as responsible for inflammation in UC ([@bib28]). However, a more nuanced understanding of the role of T cells in IBD has lead to the implication of Th17 cells in CD pathogenesis as well. Th17 cells are characterized by the expression of the transcription factor RORγt^+^ and produce high levels of the cytokines IL-17 and IL-22. High levels of these cytokines have been found in the gut mucosa of CD patients as compared to healthy controls ([@bib17]; [@bib2]). More recently, IFN-γ, a Th1 cell cytokine, IL-17 and IL-22 have been shown to be increased in the affected ileum compared to the uninfected ileum of CD patients ([@bib40]). Because it is still unclear whether dysbiosis precedes inflammation, the initiation of an adaptive response to the gut microbiota in IBD still needs to be fully elucidated. Herein, we have utilized 16S rRNA gene amplicon sequencing, shotgun metagenomic sequencing, and analysis of immune cell populations in the gut to demonstrate that the risk allele T300A affects gut microbial composition in mice, both during inflammation under conventional housing conditions, and also in gnotobiotically-housed mice that harbor microbial communities derived from stool specimens from IBD patients, or in mice associated with *Bacteroides ovatus* with a limited, defined microbial community. Furthermore, we have shown that these differences can affect the immune response in the gut lamina propria (LP) prior to the manifestation of disease.

Results {#s2}
=======

T300A conventionally-housed specific-pathogen-free (SPF) mice display altered gut microbial composition at steady state {#s2-1}
-----------------------------------------------------------------------------------------------------------------------

Previous studies have shown that IBD risk alleles can affect microbial composition ([@bib33]). Because ATG16L1 is involved in the handling of intracellular bacteria, we asked whether the IBD risk allele T300A could affect the gut microbiota in conventionally-housed SPF wild type (WT) vs. T300A knockin mice ([@bib39]) at steady state. We conducted 16S rRNA gene amplicon surveys on stool samples from WT and T300A mice ([Figure 1](#fig1){ref-type="fig"}). We observed overall alterations in the microbiota of T300A mice compared to WT mice ([Figure 1a](#fig1){ref-type="fig"}). WT and T300A mice showed distinct separation by t-distributed stochastic neighbor embedding (t-SNE) analysis ([Figure 1b](#fig1){ref-type="fig"}) and we saw an increase in the order Bacteroidales ([Figure 1c](#fig1){ref-type="fig"}). Overall, these data suggest that T300A mice have alterations in the gut microbiota at steady state and that the abundance of the order Bacteroidales may be influenced by the presence of the T300A IBD risk allele in mice.

![Altered microbiota in conventionally-housed WT vs T300A mice.\
12 week old WT and T300A mice were conventionally-housed in a specific pathogen free (SPF) facility. Stool samples were collected and analyzed by 16S rRNA gene amplicon sequencing. (**a**) Population analysis of 16S rRNA gene amplicon sequencing from stool samples from SPF WT vs. T300A mice. (p = phylum, c = class, o = order, f = family, g = genus, s = species) Bacteria Z-scores generated by limma. (**b**) t-Distributed Stochastic Neighbor Embedding (tSNE) plot analysis of WT vs. T300A SPF mouse stool samples. (**c**) Box plot analysis of the order Bacteroidales in WT vs. T300A SPF mouse stool samples.](elife-39982-fig1){#fig1}

T300A conventionally-housed mice display altered gut microbial composition and an increased abundance of bacteroidetes including *Bacteroides ovatus* during gut inflammation {#s2-2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Given that the alterations observed in the human gut IBD microbiota are often studied in the context of gut inflammation and injury, we sought to determine whether the T300A allele would influence the gut microbiota in mice during a state of large intestinal injury and inflammation modeled using a chemical-based perturbation, as T300A mice do not spontaneously develop intestinal inflammation. We treated WT and T300A mice with 2.5% dextran sulfate sodium (DSS) in the drinking water for 7 days followed by 7 days of regular drinking water. We conducted 16S rRNA gene amplicon surveys on stool specimens after this two-week intervention from WT and T300A mice ([Figure 2](#fig2){ref-type="fig"}). We observed a decrease in the phylum Firmicutes and an increase in the phyla Bacteroidetes, Proteobacteria, and Cyanobacteria in T300A mice as compared to WT mice ([Figure 2a](#fig2){ref-type="fig"}). The microbiota of WT mice separated from cage-matched T300A mice by t-distributed stochastic neighbor embedding (t-SNE) analysis ([Figure 2b](#fig2){ref-type="fig"}). These data support that T300A plays a role in shaping the gut microbiota in the context of intestinal injury and recovery. When we looked specifically at the phyla Bacteroidetes, there was an increased abundance in T300A mice compared to WT mice ([Figure 2c](#fig2){ref-type="fig"}) suggesting that the T300A risk allele may specifically enhance *Bacteroides spp*. In particular, *B. ovatus* was increased significantly in T300A mice ([Figure 2d](#fig2){ref-type="fig"}). We analyzed the data using PICRUSt in order to infer metabolic function and found increased glycosaminoglycan degradation in samples from T300A mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), a process which is uniquely attributed to Bacteroidetes ([@bib35]). The degradation of glycosaminoglycans by Bacteroidetes has the potential to affect gut barrier function by reducing the thickness and integrity of the mucus layer and in turn contributes to bacterial translocation and host immune system activation. This observation has implications for the mechanism by which increased abundance of Bacteroidetes can contribute to disease pathogenesis in IBD. Additionally, we also observed increased weight loss in T300A mice from day 8 through 13 following treatment with DSS compared to WT mice, suggesting that these alterations in the microbiota are associated with heightened disease susceptibility ([Figure 2e](#fig2){ref-type="fig"}).

![Altered microbiota in conventionally-housed WT vs T300A mice with gut inflammation.\
12 week old WT and T300A conventionally-housed SPF mice were treated with 2.5% DSS for 7d followed by 7d of regular drinking water. (**a**) Population analysis of 16S rRNA gene amplicon sequencing from stool samples from WT vs. T300A mice. (p = phylum, c = class, o = order, f = family, g = genus, s = species) Bacteria Z-scores generated by limma. (**b**) t-Distributed Stochastic Neighbor Embedding (tSNE) plot analysis of WT vs. T300A stool samples post DSS treatment. (**c**) Box plot analysis of the phylum Bacteroidetes in WT vs. T300A mice post DSS treatment. (**d**) Box plot analysis of *B. ovatus* in WT vs. T300A mice post DSS treatment. (**e**) Percent initial body weight of WT (n = 12) and T300A (n = 15) mice treated with 2.5% DSS for 7d followed by 7d of regular drinking water. Day 8--13 time points, p = \< 0.0001. Two-way ANOVA with Tukey's post-hoc test.\
10.7554/eLife.39982.006Figure 2---source data 1.Source data for [Figure 2](#fig2){ref-type="fig"}.](elife-39982-fig2){#fig2}

Human stool donor disease status shapes gut microbiota composition in mice {#s2-3}
--------------------------------------------------------------------------

Next, we sought to determine whether the differences observed in the microbial community in T300A conventionally-housed mice during inflammation were specific to the mouse microbiome or whether the host T300A genotype could also influence the composition of donor human stool. We obtained a limited number of human stool samples from patients with a genotype of WT or T300A and with active or inactive disease status to associate germ-free (GF) mice. It should be noted that the T300A allele is a relatively common mutation in healthy individuals ([@bib24]), thus our healthy control is heterozygous for T300A based on the availability of stool samples. First, to verify that patient stool samples would maintain a composition based on human donor disease status within the mouse gut, we orally inoculated WT and/or T300A gnotobiotically-housed mice with stool samples from two CD patients in remission (donor genotype T300A or WT, termed 'inactive CD'), a CD patient with active inflammation (genotype T300A, termed 'active CD'), an ulcerative colitis (UC) patient with active inflammation (genotype T300A, termed 'active UC'), or a healthy volunteer (genotype heterozygous T300A (AG), termed 'healthy control') ([Figure 3a](#fig3){ref-type="fig"}). We compared the phylogenetic compositions from 16S rRNA gene amplicon sequencing data from the original human donor stool samples with phylogenetic composition analyses from our shotgun metagenomic data using MetaPhlAn from stool samples from GF mice associated with the indicated human stool samples. We observed that samples from these mice maintained diversity based on patient disease status by PCA analysis ([Figure 3a](#fig3){ref-type="fig"}). Individual mice associated with the same patient stool clustered together with the original samples from human donor samples used for the GF associations. This observation suggested that the differences in the human microbiome from patient samples were maintained within the mouse gut.

![Distinct gut microbiota composition in mice associated with human stool.\
GF mice were associated with human stool samples and analyzed after four wks. (**a**) tSNE dimensionality reduction analysis based on genus-level abundances of stool samples from human patient stool donor (square) or GF WT (circles) and T300A (triangles) mice four wks post association with 50 mg human stool from patients: healthy control, genotype Het (yellow), inactive CD, genotype WT (blue), inactive CD, genotype T300A (green), active CD, genotype T300A (red), or active UC, genotype T300A (purple). Each symbol represents data from an individual mouse. (**b**) PCA plot of stool samples from WT vs. T300A mice four wks post association with either active CD (left) or active UC (right) human stool. Each symbol represents data from an individual mouse.](elife-39982-fig3){#fig3}

T300A alters gut microbiota composition in gnotobiotically-housed mice associated with active CD stool {#s2-4}
------------------------------------------------------------------------------------------------------

To determine whether the presence of T300A could alter the gut microbiota, we orally inoculated human stool from individual IBD patients with active disease (one with CD or one with UC) into gnotobiotically-housed WT or T300A mice. Four weeks after oral inoculation, we assessed the stool microbial composition by metagenomic sequencing and MetaPhlAn followed by PCA analysis ([Figure 3b](#fig3){ref-type="fig"}). We observed a difference in WT vs. T300A mice by PCA in mice that received stool from a CD patient with active disease but not in mice inoculated with stool from a UC patient with active disease ([Figure 3b](#fig3){ref-type="fig"}). These data suggest that differences in the active CD microbiota in mice are due to the presence of the risk allele T300A as opposed to microbial population drift due to human stool transfer into mice alone. When we examined the microbial composition of WT vs. T300A mice associated with stool from IBD patients with active disease, we observed an increase in the genus *Bacteroides* in T300A mice that received stool from patients with active CD as compared to WT mice ([Figure 4a](#fig4){ref-type="fig"}). *B. ovatus* was also increased in T300A mice that received stool from patients with active CD ([Figure 4b](#fig4){ref-type="fig"}), further supporting the idea that T300A has the potential to drive increases in *Bacteroides spp*. We did observe high levels of *Bacteroides* in mice that received stool from patients with active UC but no significant difference between WT and T300A mice ([Figure 4b](#fig4){ref-type="fig"}). We did not see major significant changes to the microbiota in WT vs. T300A mice associated with active UC stool. These data suggest that the human CD microbiota may be more susceptible to the presence of T300A, driving larger differences in microbial populations compared to mice associated with stool from patients with active UC.

![T300A alters gut microbiota composition in GF mice associated with human stool.\
Metagenomic population analysis (MetaPhlAn) on stool samples (four wk time point) from WT vs. T300A GF mice associated with human IBD stool samples (**a**) Box plot of the genus *Bacteroides* from stool samples from mice associated with active CD or active UC stool samples. (**b**) Box plot of *B. ovatus* from stool samples from mice associated with active CD or active UC stool samples. P-values were generated using Benjamini-Hochberg false discovery rate. (**a, b**) Y-axis is log10 relative abundance.](elife-39982-fig4){#fig4}

Presence of T300A in humans increases *Bacteroides* {#s2-5}
---------------------------------------------------

Previous reports on the abundance of Bacteroidetes show conflicting results in humans ([@bib25]), with some studies reporting an increased abundance while others report a decreased abundance in patients with IBD. Therefore, we investigated whether the increase in *Bacteroides* in the microbiota of T300A mice was also seen in IBD patients with the risk allele T300A ([Figure 5](#fig5){ref-type="fig"}). We utilized patient genotype data and stool microbiome data available from a previous study ([@bib29]). When we compared the microbiota from IBD patients with WT (AA) genotype versus heterozygous patients (AG) versus T300A (GG) genotype, we saw a trend toward an increase in the genus *Bacteroides* ([Figure 5a](#fig5){ref-type="fig"}). We also observed a trend toward an increase in the *B. fragilis* group ([Figure 5b](#fig5){ref-type="fig"}) and a significant increase in the species *Bacteroides caccae* ([Figure 5c](#fig5){ref-type="fig"}). In contrast, we observed a decrease in *Clostridia* and an increase in *Gammaproteobacteria* ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) both of which have been observed in numerous human IBD studies ([@bib16]; [@bib20]; [@bib58]) and pre-clinical colitis models ([@bib61]; [@bib19]). These data show that the presence of T300A has the potential to reconfigure the human microbiota and that the presence of a heterozygous genotype displays an intermediate phenotype with *Bacteroides spp,* suggesting that even a mild alteration in ATG16L1 can have an effect on bacterial abundance. This association of the risk allele T300A and alterations in the microbiota have not previously been described. This link between genotype and gut microbial phenotype in humans is important for furthering our understanding of the basis of IBD pathogenesis. Whether or not genotype and the microbiota are also associated with differences in immune populations in humans, prior to IBD disease onset or recrudescence is yet to be determined.

![The presence of T300A in humans increases *Bacteroides*.\
16S rRNA gene amplicon data from human stool samples from Jostins et al. 2012 ([@bib29]) cohort were analyzed for differences in the microbiota associated with the presence (T300A -- GG), absence (WT -- AA) or heterozygous (Het -- AG) genotype. (g = genus, s = species). (**a**) Relative abundance of *Bacteroides*. (**b**) Relative abundance of *B. fragilis*. (**c**) Relative abundance of *B. caccae*.](elife-39982-fig5){#fig5}

T300A selectively alters gut immune cell populations in mice associated with active CD patient stool {#s2-6}
----------------------------------------------------------------------------------------------------

We sought to discern whether the alterations we observed in the gut microbiota of T300A mice were also associated with changes in immune cell populations in the gut of gnotobiotic WT versus T300A mice associated with patient stool. Crohn's disease has been linked to an increase in both Th17 cells and Th1 cells in the gut ([@bib54]; [@bib17]; [@bib2]; [@bib40]). Th17 and Th1 cells are characterized by the expression of the transcription factors RORγt and T-bet respectively. Therefore, we analyzed RORγt^+^ (Th17) and T-bet^+^ (Th1) T cells in addition to Foxp3^+^ regulatory T cells (Treg), as well as GATA-3^+^ (Th2) cells by flow cytometry from mice associated with stool from patients with active CD or active UC ([Figure 6](#fig6){ref-type="fig"}). T cells were gated as the frequency of CD3^+^CD4^+^, live, CD45^+^, lymphocytes ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Myeloid cells can also play a role in inflammation during IBD, and loss of ATG16L1 in myeloid and dendritic cells leads to enhanced colitis and increased production of inflammatory cytokines ([@bib76]). Thus, we analyzed the following myeloid cell populations: CD11c^+^MHCII^+^ conventional dendritic cells (DCs), CD11b^-^CD103^+^ tolerogenic DCs, CD11b^+^GR-1^int^ neutrophils, and CD11b^+^GR-1^hi^ inflammatory monocytes by flow cytometry ([Figure 6](#fig6){ref-type="fig"}). Conventional DCs, neutrophils and inflammatory monocytes were gated out of live, CD45^+^ cells and tolerogenic DCs were gated out of conventional DCs ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}). We examined the frequency of T cell populations and myeloid cell populations in the lamina propria (LP) of the colon and ileum from WT and T300A mice associated with stool from patients with either active CD or active UC ([Figure 6](#fig6){ref-type="fig"}). We observed increased frequencies of Th17 and Th1 T cells exclusively in the LP of the colon and ileum from T300A mice that received stool from patients with active CD ([Figure 6a and c](#fig6){ref-type="fig"}) and not in the LP of the colon or ileum of mice that received stool from patients with active UC ([Figure 6b and d](#fig6){ref-type="fig"}). These data support an association between alterations in the gut microbiota driven by the risk allele T300A and increased frequencies of Th17 and Th1 T cells in the gut LP. We also found an increase in the frequency of Tregs in the LP of the colon from T300A mice associated with stool from patients with CD ([Figure 6a](#fig6){ref-type="fig"}) and a minor increase in the ileum in T300A mice associated with stool from patients with UC ([Figure 6d](#fig6){ref-type="fig"}). The only differences we observed in myeloid cells occurred in the LP of the colon from mice associated with stool from patients with active CD ([Figure 6a](#fig6){ref-type="fig"}). We saw a reduced frequency of conventional DCs and a slight increase in the frequency of tolerogenic DCs along with a decrease in neutrophils and inflammatory monocytes in T300A mice ([Figure 6a](#fig6){ref-type="fig"}). Why some of these populations are reduced is yet to be determined. Overall these data suggest that the presence of the T300A allele in mice can enhance Th17 and Th1 cells in the LP of the colon and ileum and alter the frequency of DCs, neutrophils, and inflammatory monocytes in the presence of stool from patients with active CD. It should be noted that histology-based grading of the colon and small intestine from mice associated with human IBD stool showed no signs of colitis, enteritis, or any intestinal histopathology ([Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}). This suggests that an alteration in the microbiota composition and alterations in gut immune cells occur before the onset of disease as assessed by histology. Whether specific microbes are responsible for differences in individual subsets of immune cells in the absence of disease is not well understood.

![Alterations in T cell and myeloid cell populations in the gut of T300A mice associated with stool from patients with active Crohn's disease.\
LP flow cytometry of T and myeloid cell populations from GF mice associated with 50 mg of frozen stool from a patient with Crohn's disease (CD, WT *n* = 6 and T300A *n* = 6) or ulcerative colitis (UC, WT *n* = 7 and T300A *n* = 5) for four wks. T cells gated as the frequency of RORγt^+^ (Th17), T-bet^+^ (Th1), Foxp3^+^ (Treg) or GATA-3^+^ (Th2) cells out of CD3^+^CD4^+^ cells and myeloid cells gated as the frequency of CD11c^+^MHCII^+^ cells out of CD45^+^ cells (conventional DCs), CD11b^-^CD103^+^ cells out of CD11c^+^MHCII^+^ cells (tolerogenic DCs), CD11b^+^GR-1^int^ cells out of CD45^+^ cells (neutrophils), and CD11b^+^GR-1^hi^ cells out of CD45^+^ cells (inflammatory monocytes). CD3^+^CD4^+^ and myeloid cell populations were gated on single, live, CD45^+^ lymphocytes. (**a**) GF +CD stool colonic LP T cells (top) and myeloid cells (bottom) (**b**) GF +UC stool colonic LP T cells (top) and myeloid cells (bottom). (**c**) GF +CD stool ileal LP T cells (top) and myeloid cells (bottom) (**d**) GF +UC stool ileal LP T cells (top) and myeloid cells (bottom). Data are plotted as the mean ± SEM. ns = not significant. Mann-Whitney *U* test.\
10.7554/eLife.39982.015Figure 6---source data 1.Source data for [Figure 6](#fig6){ref-type="fig"}.](elife-39982-fig6){#fig6}

T300A selectively enhances Th17 cells in the gut of mice with a restricted, defined microbiota in the presence of *Bacteroides ovatus* {#s2-7}
--------------------------------------------------------------------------------------------------------------------------------------

Previous studies support that *Bacteroides spp*. can drive a Th17 response in the colon ([@bib69]), suggesting that the increase we observe in Th17 cells in the LP of the colon from T300A mice could be driven by the increase in *Bacteroides* in these mice (see [Figure 4](#fig4){ref-type="fig"}). Therefore, we assessed whether the presence of *B. ovatus,* a species that we observed increased in abundance in T300A mice associated with active CD stool, would selectively alter gut immune populations in T300A mice. To test this hypothesis we associated GF and altered Schaedler flora (ASF), a restricted, defined microbial community of eight bacterial members, WT and T300A mice with \~10^9^ CFU of *B. ovatus* 8483 for 3 weeks. Because it has been shown that housing of mice in separate cages can affect the composition of the gut microbiota, WT and T300A mice were co-housed during the association of all studies performed with *B. ovatus* 8483. Information on caging, age, and sex of mice for all studies can be found in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. We found no difference in any immune populations in WT or T300A GF mice or GF mice associated solely with *B. ovatus* 8483 ([Figure 7](#fig7){ref-type="fig"}). However, T300A ASF mice showed an increase only in Th17 cells in the LP of the colon and ileum when *B. ovatus* 8483 was present ([Figure 8b and d](#fig8){ref-type="fig"}), but there was no difference in ASF mice in the absence of *B. ovatus* 8483 ([Figure 8a and c](#fig8){ref-type="fig"}). Besides a slight decrease in Th1 cells in the ileum of T300A ASF mice in the presence of *B. ovatus* 8483 ([Figure 8d](#fig8){ref-type="fig"}), there were no other changes in the immune populations analyzed. These data suggest that the presence of the T300A allele and additional members of the microbiota can increase the presence of Th17 cells in the gut. This increase in frequency of Th17 cells in T300A ASF mice with *B. ovatus* 8483 also occurred in the absence of colitis, enteritis, or any intestinal histopathology ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}), or differences in the level of colonization of WT and T300A mice with *B. ovatus* 8483 ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). This demonstrates that the differences in Th17 cells in ASF T300A *B. ovatus* 8483 mice were not due to an increase in colonization of *B. ovatus* but rather were most likely due to the presence of the T300A allele alone.

![No change in immune cell population frequency in the gut of GF or GF mice monoassociated with *B. ovatus* 8483.\
LP flow cytometry of T and myeloid cell populations from GF mice (WT *n* = 6, T300A *n* = 6) or GF mice associated with \~10^9^ CFU of *B. ovatus* 8483 for three wks (WT *n* = 6, T300A *n* = 6). T cell populations are gated as the frequency of RORγt^+^ (Th17), T-bet^+^ (Th1), Foxp3^+^ (Treg) or GATA-3^+^ (Th2) cells out of CD3^+^CD4^+^ cells and myeloid cell populations are gated as the frequency of CD11c^+^MHCII^+^ cells out of CD45^+^ cells (conventional DCs), CD11b^-^CD103^+^ cells out of CD11c^+^MHCII^+^ cells (tolerogentic DCs), CD11b^+^GR-1^int^ cells out of CD45^+^ cells (neutrophils), and CD11b^+^GR-1^hi^ cells out of CD45^+^ cells (inflammatory monocytes). CD3^+^CD4^+^ and myeloid cell populations were gated on single, live, CD45^+^ lymphocytes. (**a**) GF colonic LP T cells (top) and myeloid cells (bottom) (**b**) GF +*B. ovatus* 8483 colonic LP T cells (top) and myeloid cells (bottom). (**c**) GF ileal LP T cells (top) and myeloid cells (bottom) (**d**) GF +*B. ovatus* 8483 ileal LP T cells (top) and myeloid cells (bottom). Data are plotted as the mean ± SEM. ns = not significant. Mann-Whitney *U* test.\
10.7554/eLife.39982.017Figure 7---source data 1.Source data for [Figure 7](#fig7){ref-type="fig"}.](elife-39982-fig7){#fig7}

![Increased frequency of Th17 cells in the gut of T300A ASF mice associated with *B. ovatus* 8483.\
LP flow cytometry of T cell and myeloid cell populations from ASF mice (WT *n* = 6 and T300A *n* = 6) or ASF mice associated with \~10^9^ CFU of *B. ovatus* 8483 for 3 weeks (WT *n* = 6 and T300A *n* = 6). T cells gated as the frequency of RORγt^+^ (Th17), T-bet^+^ (Th1), Foxp3^+^ (Treg) or GATA-3^+^ (Th2) cells out of CD3^+^CD4^+^ cells and myeloid cell gated as the frequency of CD11c^+^MHCII^+^ cells out of CD45^+^ cells (conventional DCs), CD11b^-^CD103^+^ cells out of CD11c^+^MHCII^+^ cells (tolerogentic DCs), CD11b^+^GR-1^int^ cells out of CD45^+^ cells (neutrophils), and CD11b^+^GR-1^hi^ cells out of CD45^+^ cells (inflammatory monocytes). CD3^+^CD4^+^ cell and myeloid cell populations were gated on single, live, CD45^+^ lymphocytes. (**a**) ASF colonic LP T cells (top) and myeloid cells (bottom) (**b**) ASF +*B. ovatus* 8483 colonic LP T cells (top) and myeloid cells (bottom). (**c**) ASF ileal LP T cells (top) and myeloid cells (bottom) (**d**) ASF +*B. ovatus* 8483 ileal LP T cells (top) and myeloid cells (bottom). Data are plotted as the mean ± SEM. ns = not significant. Mann-Whitney *U* test.\
10.7554/eLife.39982.021Figure 8---source data 1.Source data for [Figure 8](#fig8){ref-type="fig"}.](elife-39982-fig8){#fig8}

The presence of *Bacteroides ovatus* increases the expression of *Il23p19* in T300A ASF mice {#s2-8}
--------------------------------------------------------------------------------------------

The increase in Th17 cells in the gut of T300A ASF mice associated with *B. ovatus* prompted us to look at expression levels of the IL-23 specific subunit, IL-23p19, in the LP of the colon and ileum from T300A mice ([Figure 9](#fig9){ref-type="fig"}). IL-23 induces IL-17 producing cells that can induce inflammation ([@bib38]) and is essential for the production of IL-17 in T-cell mediated colitis ([@bib75]). Additionally, antibodies targeting IL-23 have been utilized as a treatment for IBD and antibodies specific for IL-23p19 show promising clinical trial results ([@bib48]), suggesting that IL-23 plays an important role in IBD pathogenesis. We found that in T300A ASF mice, the presence of *B. ovatus* 8483 increased expression levels of *Il23p19* in the LP of both the colon ([Figure 9a](#fig9){ref-type="fig"}) and ileum ([Figure 9b](#fig9){ref-type="fig"}). Overall, these results demonstrate that the presence of *B. ovatus* 8483 in the context of the T300A allele and a minimal microbiota can enhance both IL-23 expression and Th17 cell infiltration into the gut before the onset of disease symptoms in mice.

![Increased expression of *Il23p19* in the lamina propria from the colon and ileum of T300A ASF mice associated with *B. ovatus* 8483.\
Expression of *Il23p19* by qPCR from colon (**a**) and ileum (**b**) LP cells isolated from ASF T300A mice or ASF T300A mice associated with *B. ovatus* 8483.\
10.7554/eLife.39982.023Figure 9---source data 1.Source data for [Figure 9](#fig9){ref-type="fig"}.](elife-39982-fig9){#fig9}

Discussion {#s3}
==========

The role of the gut microbiota in IBD pathogenesis is well established, but how and when microbial dysbiosis occurs during disease progression is less well understood. The identification of IBD genetic risk loci involved in the processing and handling of microbes provides more definitive clues into disease pathogenesis. However, we still do not fully understand how host genotype or particular SNPs influence microbial community assembly, community composition, or function. The reduced barrier integrity associated with defects in Paneth cell anti-microbial peptide secretion in T300A hypomorphic mice ([@bib6]) and T300A knock-in mice ([@bib8]), and increased production of inflammatory cytokines by ATG16L1 deficient innate immune cells in response to infiltrating bacteria ([@bib63]) can activate an adaptive immune response to the gut microbiota. However, whether genetic risk loci directly affect specific gut microbial population frequency is not known. Here we show that the presence of the CD risk allele *ATG16L1 *T300A in both mice and humans can shape the gut microbiota. More specifically, it can enhance the abundance of *Bacteroides*, including *B. ovatus*, as well as increase the local Th1 and Th17 response in the gut LP in T300A mice associated with stool from a patient with active CD but not stool from a patient with active UC.

We found that minimal microbiota ASF T300A mice associated with *B. ovatus* 8483, specifically increased Th17 cells, suggesting that the other differences we saw in Treg and myeloid cell populations in T300A mice associated with stool from a patient with active CD may be due to the presence of other species in the CD microbiota. While we observe increases in other microbial populations, including Proteobacteria and Cyanobacteria in conventional-housed T300A subjected to chemically-induced inflammatory conditions, the increase in Bacteroidetes was common between both DSS-treated conventionally-housed mice and gnotobiotically-reared human stool associated mice, suggesting that T300A could potentially be a driver of increased Th17 and Th1 T cell populations in the gut LP via increased *Bacteroides spp*. When T300A ASF mice were associated with *B. ovatus* 8483, we did not observe differences in levels of colonization, suggesting that the increase in the frequency of Th17 T cells in the gut LP was independent of the level of colonization. Why we did not find differences in immune populations in GF WT and T300A mice monocolonized with *B. ovatus* 8483 is intriguing as it suggests that this increase in Th17 cells requires the presence of a more complex microbiota. Future work will be needed to elucidate how the immune response to *B. ovatus* changes in the presence of additional microbial species and in the context of distinct host genotypes associated with IBD. Specifically, what is the nature of the co-occurrence relationships between *B. ovatus* and other members of a microbiota necessary for Th17 T cell expansion? Alternatively, are there a series of one-on-one host-microbe relationships in tandem or sequentially that are required for Th17 T cell expansion in the LP of the colon and ileum?

Previous studies have demonstrated the ability of individual *Bacteroides spp*. to induce IBD in genetically susceptible mice ([@bib4]) and others have shown that *Bacteroides spp*. can induce IL-17 response in the gut ([@bib69]). Exactly how T300A could enhance *Bacteroides* specifically is yet to be determined. We found that expression of a subunit of IL-23, *Il23p19,* a cytokine known to increase IL-17 production from T cells, was increased in both the LP of the colon and the ileum from T300A mice associated with *B. ovatus* 8483. Other studies have shown that *B. fragilis* enterotoxin can induce formation of autophagosomes ([@bib34]). Another report demonstrated that ATG16L1 is required to generate a regulatory T cell response to *B. fragilis* outer membrane vesicles ([@bib7]). Because T300A is susceptible to caspase 3 cleavage and is preferentially targeted for degradation compared to WT ATG16L1 ([@bib72]), reduced xenophagy levels could allow for an outgrowth of *Bacteroides*, and an insufficient regulatory T cell response necessary to dampen Th17 population expansion. ATG16L1 and Nod2 (another CD risk allele) have been shown to interact in an autophagy-dependent antibacterial pathway ([@bib26]), suggesting that defects in either pathway could affect *Bacteroides* abundance. For example, Nod2 is essential for preventing the expansion of *Bacteroides vulgatus* in mice ([@bib57]). We also saw that T300A in humans was associated with a trend in increased levels of *Bacteroides* including the *B. fragilis* group and a significant increase in *B. caccae* which is closely related to *B. ovatus* ([@bib64]). An intermediate phenotype was seen in people with the heterozygous (AG) genotype. More research, especially in a prospective cohort of at-risk individuals, will be needed to determine whether IBD patients with T300A have an increase in *B. ovatus* prior to disease onset and whether this contributes to disease pathogenesis.

IBD symptoms can vary in nature and severity as well as disease location. While some patients will respond to treatment, others will not, suggesting that subtypes of the disease may be dependent on both genetics and the microbiota. Healthy individuals and CD patients may harbor multiple risk alleles, compounding the effect of specific alleles on the microbiota, and further studies will be needed to address the complexity of genetic associations with gut microbial composition. However, understanding how risk alleles can shape both the microbiota and the underlying immune response, in tandem, can provide insight into identifying subsets of the disease as well as inform diagnosis and treatment decisions. We have shown that the risk allele *ATG16L1 *T300A, a SNP associated with an increased risk of CD, contributes to dysbiosis in mice, specifically an increase in *Bacteroides* among other alterations, and correlates with an enhanced Th1 and Th17 immune response in the gut LP. These changes precede the onset of disease in human stool microbiome associated mice, suggesting that microbiota changes induce inflammatory cell population shifts in the gut. These results shed light on the etiology of CD and provide insight into the relationship between SNPs, dysbiosis and the immune response in the gut.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\           Designation                                           Source or\                                                             Identifiers                                                                         Additional information
  or resource                                                                             reference                                                                                                                                                  
  --------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------
  Genetic reagent (*M. musculus*)   T300A                                                 PMID: 24821797                                                                                                                                             Dr. Ramnik Xavier (Broad/MIT/Harvard)

  Chemical compound, drug           Dextran Sulfate Sodium                                MP Biomedicals                                                         0216011050--50 g                                                                    

  , strain back ground              *Bacteroides ovatus*                                  ATCC                                                                   8483                                                                                

  Software, algorithm               Picard suite                                          <https://broadinstitute.github.io/picard/command-line-overview.html>   RRID:[SCR_006525](https://scicrunch.org/resolver/SCR_006525)                        

  Software, algorithm               MetaPhlAn                                             PMID 26418763                                                          RRID:[SCR_004915](https://scicrunch.org/resolver/SCR_004915)                        

  Software, algorithm               HUMAnN2                                               <http://huttenhower.sph.> harvard.edu/humann2                          RRID:[SCR_016280](https://scicrunch.org/resolver/SCR_016280)                        

  Software, algorithm               Rtsne                                                 <https://cran.r-project.org/web/packages/Rtsne/index.html>             RRID:[SCR_016342](https://scicrunch.org/resolver/SCR_016342)                        

  Software, algorithm               PICRUSt                                               PMID 23975157                                                          RRID: [SCR_016856](https://scicrunch.org/resolver/SCR_016856)                       

  Software, algorithm               HUMAnN                                                PMID 22719234                                                          RRID:[SCR_014620](https://scicrunch.org/resolver/SCR_014620)                        

  Software, algorithm               Prism 7.0b                                            <https://www.graphpad.com/scientific-software/prism/>                  RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)                        

  Software, algorithm               limma                                                 PMID 25605792                                                          RRID:[SCR_010943](https://scicrunch.org/resolver/SCR_010943)                        

  Software, algorithm               QIIME                                                 PMID:\                                                                 RRID:[SCR_008249](https://scicrunch.org/resolver/SCR_008249)                        
                                                                                          20383131                                                                                                                                                   

  Antibody                          Rat anti mouse CD16/32 (clone 93)                     Biolegend                                                              Cat. \#: 101310, RRID:[AB_2103871](https://scicrunch.org/resolver/AB_2103871)       Flow cytometry (FC), FC receptor block 1:100

  Antibody                          Rat anti mouse CD45 (clone 30-F11)                    Biolegend                                                              Cat. \#: 103114, RRID:[AB_312979](https://scicrunch.org/resolver/AB_312979)         FC, PE/Cy7 1:100

  Antibody                          Armenian hamster anti mouse CD3e (clone 145--2 C11)   Biolegend                                                              Cat. \#: 100334, RRID:[AB_2028475](https://scicrunch.org/resolver/AB_2028475)       FC, Pacific Blue 1:100

  Antibody                          Rat anti mouse CD4 (clone GK1.5)                      Biolegend                                                              Cat. \#: 100414, RRID:[AB_312981](https://scicrunch.org/resolver/AB_312981)         FC, APC/Cy7 1:100

  Antibody                          Mouse anti mouse GATA-3 (clone L50-823)               BD Biosciences                                                         Cat. \#: 560077, RRID:[AB_1645303](https://scicrunch.org/resolver/AB_1645303)       FC, Alexa Fluor 488 1:33

  Antibody                          Mouse anti mouse Foxp3 (clone 150D)                   Biolegend                                                              Cat. \#: 320007, RRID:[AB_492981](https://scicrunch.org/resolver/AB_492981)         FC, PE 1:40

  Antibody                          Rat anti mouse RORgt (clone B2D)                      Invitrogen                                                             Cat. \#: 17-6981-82, RRID:[AB_2573254](https://scicrunch.org/resolver/AB_2573254)   FC, APC 1:40

  Antibody                          Mouse anti mouse T-bet (clone 4B10)                   Biolegend                                                              Cat. \#: 644806, RRID:[AB_1595488](https://scicrunch.org/resolver/AB_1595488)       FC, PerCP/Cy5 1:33

  Antibody                          Rat anti mouse CD45 (clone 30-F11)                    Biolegend                                                              Cat. \#: 103126, RRID:[AB_493535](https://scicrunch.org/resolver/AB_493535)         FC, Pacific Blue 1:100

  Antibody                          Armenian hamster anti mouse CD11c (clone N418)        Biolegend                                                              Cat. \#: 117306, RRID:[AB_313775](https://scicrunch.org/resolver/AB_313775)         FC, FITC 1:200

  Antibody                          Rat anti mouse CD11b (clone M1/70)                    Biolegend                                                              Cat. \#: 101228, RRID:[AB_893232](https://scicrunch.org/resolver/AB_893232)         FC, PerCP/Cy5 1:200

  Antibody                          Rat anti mouse I-A/I-E (MHCII) (clone M5/114.15.2)    Biolegend                                                              Cat. \#: 107630, RRID:[AB_2069376](https://scicrunch.org/resolver/AB_2069376)       FC, PE/Cy7 1:200

  Antibody                          Rat anti mouse Ly-6G/Ly-6C (GR-1) (clone RB6-8C5)     Biolegend                                                              Cat. \#: 108412, RRID:[AB_313377](https://scicrunch.org/resolver/AB_313377)         FC, APC 1:200

  Antibody                          Armenian hamster anti mouse CD103 (clone 2E7)         Invitrogen                                                             Cat. \#: 12-1031-82, RRID:[AB_465799](https://scicrunch.org/resolver/AB_465799)     FC, PE 1:100

  CommercialAssay or Kit            Live/Dead Fixable Yellow Dead Cell Stain              Thermo Fisher Scientific                                               Cat. \#: L34959                                                                     FC

  Commercial Assay or Kit           Quant-iT PicoGreen dsDNA Assay Kit                    Thermo Fisher Scientific                                               Cat. \#: P11496                                                                     DNA quantification

  Commercial Assay or Kit           Nextera XT DNA Library Preparation Kit                Illumina                                                               Cat. \#: FC-131--1096                                                               Sequencing libraries

  Commercial Assay or Kit           Agilent DNA 1000 Kit                                  Agilent Technologies                                                   Cat. \#: 5067--1504                                                                 Insert sizes

  Other                             RNAlater                                              Sigma                                                                  Cat. \#: R0901-500ML                                                                Solution for stool sample collection

  Commercial Assay or Kit           QIAamp 96 PowerFecal QIAcube HT Kit (5)               QIAGEN                                                                 Cat. \#: 51531                                                                      Stool DNA extraction

  Commercial Assay or Kit           Allprep DNA/RNA 96 Kit                                QIAGEN                                                                 Cat. \#: 80311                                                                      Stool DNA extraction

  Other                             IRS solution                                          QIAGEN                                                                 Cat. \#: 26000-50-2                                                                 Solution for stool DNA extraction

  Commercial\                       PowerBead Plates, Glass                               QIAGEN                                                                 Cat. \#:27500--4-EP-BP                                                              Stool DNA extraction
  Assay or Kit                                                                                                                                                                                                                                       

  Other                             Brucella agar sheeps blood/hemin/vitamin K plates     Hardy Diagnostics                                                      Cat. \#: A30                                                                        Bacterial culture plates

  Commercial Assay or Kit           Rneasy Mini Kit                                       QIAGEN                                                                 Cat. \#: 74106                                                                      RNA isolation

  Commercial Assay or Kit           iScript cDNA synthesis kit                            Bio-Rad                                                                Cat. \#:1708891                                                                     cDNA synthesis
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

All mouse strains employed are on the C57BL/6J background and were sacrificed between 8--13 weeks of age. Generation of the ATG16L1 T300A knock-in mice has been previously described by [@bib21]. Conventionally-housed mice were kept at the Massachusetts General Hospital, and all procedures were performed in accordance with the Institutional Animal Care and Use Committee at Massachusetts General Hospital. ATG16L1 T300A knock-in mice were aseptically rederived as gnotobiotic animals and maintained in semi-rigid gnotobiotic isolators under a strict 12 hr light cycle in the Harvard T. H. Chan Gnotobiotic Center for Mechanistic Microbiome Studies. All gnotobiotic experiments were performed at the Harvard T. H. Chan Gnotobiotic Center for Mechanistic Microbiome Studies and were approved and carried out in accordance with Harvard Medical School\'s Standing Committee on Animals and the National Institutes of Health guidelines for animal use and care. Mice gavaged with different stool samples from human donors were maintained in separate isolator cages. For all mouse experiments a minimum of two experiments were conducted throughout.

Dextran Sulfate Sodium treatment {#s4-2}
--------------------------------

Conventionally-housed mice were fed 2.5% (w/v) dextran sulfate sodium (DSS, MP Biomedicals; MW = 36,000--50,000) dissolved in sterile distilled drinking water ad libitum for 7 days, followed by 7 days of regular drinking water. Body weights were monitored daily. Stool samples were collected into RNAlater after the last day of regular drinking water and stored at −80°C until DNA was extracted for 16S rRNA gene amplicon sequencing.

Mouse stool sample collection and DNA extraction {#s4-3}
------------------------------------------------

Stool samples for 16S rRNA amplicon surveys were collected into RNAlater and stored at −80°C prior to DNA extraction. The samples were then stored at −80°C until shipping to the Broad Institute for DNA extraction. For DNA extraction, a combination of the QIAamp 96 PowerFecal Qiacube HT Kit (Qiagen Cat No./ID: 51531), the Allprep DNA/RNA 96 Kit (Qiagen Cat No./ID: 80311), and IRS solution (Qiagen Cat No./ID: 26000-50-2) were used with a custom protocol. One mouse stool pellet per sample was transferred into individual wells of the PowerBead plate, with 0.1 mm glass beads (Cat No./ID: 27500--4-EP-BP) on dry ice. 650 μl of 56°C heated PW1 buffer with 1:100 vol addition of 1M DTT was added directly to each sample well before lysis by bead beating on a TissueLyzer II at 20 Hz for a total of 10 min. Samples pelleted by centrifugation for 6 min at 4500 x g. Supernatants transferred to a new S block (supplied in PowerFecal Kit) and combined with 150 μl of IRS solution and vortexed briefly before 1 min incubation. Sealed samples centrifuged again for 6 min, 4500 x g and up to 450 μl of supernatant were transferred to new S block, combined with 600 μl of Buffer C4 (PowerFecal Kit), mixed by pipetting 10x and incubated at room temperature for 1 min. Samples were transferred into AllPrep 96 DNA plate on top of clean S blocks and centrifuged for 3 min at 4500 x g. Step was repeated until all sample passed through. Allprep DNA plate was placed on top of a 2 mL waste block. 500 μl AW1 buffer was added to the DNA plate which was sealed and centrifuged for 4 min at 4500 x g. 500 μl AW2 buffer was added to the DNA plate, repeating centrifuge step. Allprep DNA plate was placed on top of elution plate. 100 μl of 70°C heated EB Buffer was added to each sample column and incubated for 5 min and centrifuged for 4 min at 4500 x g to elute. Purified DNA was stored at −20°C.

Human stool sample collection for gnotobiotic mouse association studies {#s4-4}
-----------------------------------------------------------------------

Human stool samples for association with gnotobiotic mice were acquired from patients from Massachusetts General Hospital according to institutional review board \#2004P001067. Patients produced the sample at the hospital visit, and it was immediately stored at −80°C by the staff. Participants provided informed consent for the study and are part of the PRISM cohort study.

Gnotobiotic mouse association with human stool {#s4-5}
----------------------------------------------

Frozen human stool samples (50 mg/mouse) were reconstituted in sterile PBS 0.05% Cysteine (250 mg/ml). 25 mg (100 ul) was orally instilled followed by 12.5 mg (50 ul) placed on the anus and 12.5 mg (50 ul) placed on the back fur of each mouse. Stool samples and gut tissues were collected at 4 weeks post human stool association.

Gnotobiotic and ASF mouse association with bacteroides ovatus 8483 {#s4-6}
------------------------------------------------------------------

*Bacteroides ovatus* 8483 (ATCC) was grown in liquid culture with *Bacteroides* basal medium as described in Pantosti et al ([@bib53]). GF or ASF mice were gavaged with \~10^9^ CFU in 100 μl. Mice were sacrificed after 3 weeks. At sacrifice, stool samples were collected and weighed and CFU/g of stool was calculated after growth on Brucella agar plates with 5% sheep blood, hemin, and vitamin K1 (Hardy Diagnostics A30).

Sequencing and analysis of the 16S Gene {#s4-7}
---------------------------------------

16S rRNA gene libraries targeting the V4 region of the 16S rRNA gene were prepared by first normalizing template concentrations and determining optimal cycle number by way of qPCR. Two 25 μl reactions for each sample were amplified with 0.5 units of Phusion with 1X High Fidelity buffer, 200 μM of each dNTP, 0.3 μM of 515F (5'-AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCGGTAA-3') and 806rcbc0 (5'CAAGCAGAAGACGGCATACGAGATTCCCTTGTCTCCAGTCAGTCAGCCGGACTACHVGGGTWTCTAAT-3'). 0.25 μl 100x SYBR were added to each reaction and samples were quantified using the formula 1.75\^(deltaCt). To ensure minimal over-amplification, each sample was diluted to the lowest concentration sample, amplifying with this sample optimal cycle number for the library construction PCR. Four 25 μl reactions were prepared per sample with master mix conditions listed above, without SYBR. Each sample was given a unique reverse barcode primer from the Golay primer set ([@bib4] and [@bib35]). Replicates were then pooled and cleaned via Agencourt AMPure XP-PCR purification system. Purified libraries were diluted 1:100 and quantified again via qPCR (Two 25 μl reactions, 2x iQ SYBR SUPERMix (Bio-Rad, REF: 1708880 with Read 1 (5'-TATGGTAATT GT GTGYCAGCMGCCGCGGTAA-3'), Read 2 (5'-AGTCAGTCAG CC GGACTACNVGGGTWTCTAAT-3'). Undiluted samples were normalized by way of pooling using the formula mentioned above. Pools were quantified by Qubit (Life Technologies, Inc.) and normalized into a final pool by Qubit concentration and number of samples. Final pools were sequenced on an Illumina MiSeq 300 using custom index 5'-ATTAGAWACCCBDGTAGTCC GG CTGACTGACT-3' and custom Read one and Read two mentioned above. 16S data were processed using QIIME (RRID:[SCR_008249](https://scicrunch.org/resolver/SCR_008249)), and taxonomy was assigned using the Greengenes predefined taxonomy map of reference sequence OTUs to taxonomy ([@bib45]). The resulting OTU tables were checked for mislabeling^71^and contamination ([@bib32]). A median sequence depth of 24,583 per sample was obtained, and samples with fewer than 5000 filtered sequences were excluded from analysis.

Library construction {#s4-8}
--------------------

16S rRNA gene libraries were constructed as previously described ([@bib36])

Metagenomics {#s4-9}
------------

DNA samples were quantified by Quant-iT PicoGreen dsDNA Assay (Life Technologies) and normalized to a concentration of 50 pg/μl. Illumina sequencing libraries were prepared from 100 to 250 pg of DNA using the Nextera XT DNA Library Preparation kit (Illumina) according to the manufacturer's recommended protocol, with reaction volumes scaled accordingly. Prior to sequencing, libraries were pooled by collecting equal volumes (200 nl) of each library from batches of 96 samples. Insert sizes and concentrations for each pooled library were determined using an Agilent Bioanalyzer DNA 1000 kit (Agilent Technologies). Libraries were sequenced on HiSeq 2 × 101 to yield \~10 million PE reads. Post-sequencing de-multiplexing and generation of BAM and Fastq files are generated using the Picard suite (RRID:[SCR_006525](https://scicrunch.org/resolver/SCR_006525)) (<https://broadinstitute.github.io/picard/command-line-overview.html>). Metagenomic data were analyzed using MetaPhlAn (RRID:[SCR_004915](https://scicrunch.org/resolver/SCR_004915)) (v.2.2) ([@bib71]) for taxonomic profiling and HUMAnN2 (RRID:[SCR_016280](https://scicrunch.org/resolver/SCR_016280) (<http://huttenhower.sph.> harvard.edu/humann2) for functional profiling. All sequencing data generated for these studies has been deposited at SRA \#SUB4222585

Principal coordinate and bacterial heatmap plots {#s4-10}
------------------------------------------------

Principal coordinate plots were generated using t-Distributed Stochastic Neighbor Embedding (t-SNE) as implemented in the R package Rtsne (RRID:[SCR_016342](https://scicrunch.org/resolver/SCR_016342)). Bray-Curtis dissimilarity, where xsi denotes the abundance of strain s in sample i, was used as the distance measure. We followed the guidelines given by the authors (FAQ at <http://lvdmaaten.github.io/tsne/>) and selected the free parameter, perplexity, by generating mappings with perplexity values between 5 and 50 in increments of 5. Mappings with lowest error and best visual properties were obtained using perplexity = 50. We set the absent proportion data to zeros and remapped the proportions (0, 1) to the interval (1e-7, 1 - 1e-7). We transformed the proportions using logit transformation, after which the data fit a normal distribution.

PICRUSt analysis {#s4-11}
----------------

Microbial functional modules were inferred from the 16S rRNA gene amplicon sequencing using PICRUSt ([@bib37]) (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) and functional modules were reconstructed using HUMAnN ([@bib1]) (RRID:[SCR_014620](https://scicrunch.org/resolver/SCR_014620)).

Lamina Propria immune cell isolation {#s4-12}
------------------------------------

Four weeks post association with human stool, the colon and distal 10 centimeters of the small intestine (SI) were removed, opened longitudinally, and rinsed in PBS (Dulbecco's -- calcium and magnesium free) to remove fecal contents. The epithelial layer was removed using two rounds of 5 mM EDTA (10 ml/colon 25 ml/SI) rotating at 37C (round 1 includes 1 mM DTT). After removing the epithelial layer, the lamina propria was washed in PBS and chopped into \~1 mM pieces. The tissue was digested in RPMI with glutamine (Sigma) with the following: 10% FBS, 1% penicillin/streptomycin (Corning), 0.5 mg/ml Dispase (STEM cell tech), 1 mg/ml collagenase D (Roche), 50 µg/ml DNAse (Roche) in two rounds of 30 min rotating at 37C. Isolated single cells were filtered over 40 µM filter and resuspended in 5 mM EDTA followed by a wash with FACS buffer (2% FBS 1 mM EDTA). Cells were counted on the hemocytometer followed by flow cytometry analysis.

Flow Cytometry {#s4-13}
--------------

1 × 10^6^ isolated colon lamina propria or small intestine lamina propria cells were stained with LIVE/DEAD^TM^ fixable yellow dead cell stain kit (Thermo Fisher Scientific, L34959) for 15 min at room temperature. Cells were washed with FACS buffer and then stained with FC block (RRID:[AB_2103871](https://scicrunch.org/resolver/AB_2103871), Biolegend, 101310) for 10 min on ice followed by mouse extracellular fluorochrome-conjugated antibodies against mouse: CD45 (RRID:[AB_312979](https://scicrunch.org/resolver/AB_312979) and RRID:[AB_493535](https://scicrunch.org/resolver/AB_493535)), CD3 (RRID:[AB_2028475](https://scicrunch.org/resolver/AB_2028475)), CD4 (RRID:[AB_312981](https://scicrunch.org/resolver/AB_312981)), CD11c (RRID:[AB_313775](https://scicrunch.org/resolver/AB_313775)), CD11b (RRID:[AB_893232](https://scicrunch.org/resolver/AB_893232)), MHCII (RRID:[AB_2069376](https://scicrunch.org/resolver/AB_2069376)), GR-1 (RRID:[AB_313377](https://scicrunch.org/resolver/AB_313377)), and CD103 (RRID:[AB_465799](https://scicrunch.org/resolver/AB_465799)). Cells were permeabilized and fixed using the Foxp3 Fix/Perm kit (Biolegend, 421403) and stained at room temperature for 45 min with the following intracellular antibodies against mouse: RORγt (RRID:[AB_2573254](https://scicrunch.org/resolver/AB_2573254)), T-bet (RRID:[AB_1595488](https://scicrunch.org/resolver/AB_1595488)), Foxp3 (RRID:[AB_492981](https://scicrunch.org/resolver/AB_492981)), or GATA-3 (RRID:[AB_1645303](https://scicrunch.org/resolver/AB_1645303)). Flow cytometry was conducted using a BD LSR II.

Colitis score {#s4-14}
-------------

Gnotobiotically-housed mice associated with stool from human donors were sacrificed and colons were removed, opened longitudinally, placed in cassettes and fixed in 4% paraformaldehyde (Sigma-Aldrich) and embedded in paraffin. Sections (5 μM) were H and E-stained and evaluated in a blinded fashion for epithelial hyperplasia (0--3), epithelial injury (0--3), polymorphonuclear infiltration (0--3) and mononuclear infiltration (0--3).

Statistical analysis {#s4-15}
--------------------

Statistical analysis for flow cytometry data was performed in Prism 7.0b (RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)). Data are plotted as mean ± SEM and either Mann-Whitney *U* test or two-way ANOVA as described in figure legend. p \< 0.05 was considered significant. ns = not significant. To discover association of bacterial abundance and the mouse genotype, we use limma (RRID:[SCR_010943](https://scicrunch.org/resolver/SCR_010943)), an R package for linear modeling that powers differential expression analyses ([@bib60]). We adjusted for age, cage, and sex in the analysis. Corrected P-values were generated using Benjamani-Hochberg false discovery rate.

qPCR {#s4-16}
----

Expression of *Il23p19* was analyzed from total cells isolated from the colon and ileum lamina propria. Epithelial cells were removed as described in the lamina propria immune cell isolation methods described above. Lamina propria cells were resuspended in RLT buffer and frozen at −80C until further analysis. RNA was extracted using the RNeasy Mini kit (QIAGEN) and cDNA was generated using iScript cDNA synthesis Kit (Bio-Rad, 1708891). Quantitative PCR was conducted using the following primers for *Il23p19*: forward primer: AGCGGGACATATGAATCTACTAAGAGA, reverse primer: GTCCTAGTAGGGAGGTGTGAAGTTG.
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###### Mouse caging and metadata for [Figures 1](#fig1){ref-type="fig"}--[8](#fig8){ref-type="fig"}.

Mouse genotype, age (wks), sex, cage, experiment description and figure are listed above. Mice housed together have the same cage number.
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Human microbiome sequence data are available as noted in Jostins et al. 2012 and requests for access can be made via the NCBI Genotypes and Phenotypes database (additional details here <https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login>). Mouse microbiome data have been submitted for deposit at NCBI sequence read archive SUB4222585.
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AleksanderKostic2018Illumina HiSeq 2000 sequencing of SAMD00080972NCBI Sequence Read Archive4222585
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JudyCho2012NIDDK IBD Genetics Consortium Ulcerative Colitis Genome-Wide Association StudyNCBI Genotypes and Phenotypes databasephs000345.v1.p1
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Decision letter

Cadwell

Ken H

Reviewing Editor

Skirball Institute of Biomolecular Health

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"The Crohn\'s disease polymorphism, *ATG16L1T300A*, alters the gut microbiota and enhances the local Th1/Th17 response\" for peer review at *eLife*. Your article is being evaluated by three peer reviewers, and the evaluation is being overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor.

As you will see, there is consensus among the reviewers that the conclusions of the manuscript, if valid, are of great interest to the field and appropriate for publication in *eLife*. The reviewers and the Reviewing Editor all agree that the strength of the manuscript is the approach, where human IBD specimens are transferred into germ-free mice to reveal new gene-microbiome interactions. However, the absence of certain information, conditions, and controls calls into question the conclusions. The reason why certain data is missing in this study is likely due to the technically challenging and time consuming nature of this powerful approach. The reviewers are sympathetic to this challenge, and wish to give the authors an opportunity to respond. The following appear to be the big picture consensus concerns:

1\) Analysis of the microbiome composition pre-DSS (or no DSS) is necessary to interpret the findings post-DSS.

2\) The rationale for donor selection is unclear and potentially problematic. The non-T300A donors may be key to interpretation of the experiments and establishing baseline. Similarly, the T300A genotype does not appear to have a contribution towards microbiome composition in UC, although we cannot say that for sure with the current analysis. It is unclear mechanistically why it matters whether the sample is from UC vs CD with the same genotype. Also, why is the healthy control heterozygous for T300A? A related issue is the low N number for human donors. These differences between conditions (health status and genotype) may be a reflection of random donor heterogeneity.

3\) A more thorough examination of the immune compartment is needed. There is a sense that the authors are finding what they\'re looking for.

4\) Details regarding co-housing, gender, and littermates are missing. Depending on how the experiments were performed, a subset may need to be repeated under appropriate conditions to validate the initial findings.

If certain samples are readily available, and some of the concerns can be addressed through clarification of text rather than time-consuming experiment, then it may be possible to address these issues within the 2-month review period. The danger is that the authors will invest significant resources to improve the manuscript, only to find that the strategy is insufficient. Therefore, the editors and reviewers wish to invite you to respond within the next two weeks with an action plan and detailed timetable for the completion of the additional work. Please clearly state which issues will be addressed through writing versus generating new experimental results. Also, the above 4 points represent a summary of the discussion and we encourage you to carefully read and consider the detailed comments by the reviewers outlined below. We plan to share your responses with the reviewers and then issue a binding recommendation.

*Reviewer \#1:*

The Crohn disease risk allele ATG16L1 (*ATG16L1T300A*), which impacts expression of this important protein has known impacts on host immune response and results in decreased autophagy, increased pro-inflammatory cytokine release, and decreased intracellular bacterial clearance. This submitted manuscript addresses the major existing knowledge gaps regarding whether this and other genetic risk loci for IBD can also drive changes in the gut microbiota.

In this interesting work, the authors have studied a gnotobiotic model using patient fecal transfers in mice, bearing this same risk allele *ATG16L1T300A*, and determine the effects on host-microbiota interactions. Well-designed experiments reveal putative increases in certain bacteria -- viz. *Bacteroides ovatus* as well as alterations in gut Th1/Th17 cells in *ATG16L1T300A* mice, without colitis possibly prior to disease onset.

Critique:

1\) GWAS studies have linked over 230 genetic risk loci to increased IBD risk but this manuscript addresses only one and even when transferring stool from active Crohn disease patient does not cause experimental colitis per se. Further, already published work has shown that NOD2 variants, which may interact in aberrant manner with ATG16L1, predispose to dysbiosis -- see Knights et al., 2014.

2\) Alterations in mouse fecal microbiota are only noted in in SPF T300A vs. WT mice following on the generation of gut inflammation, as in Figure 1. It appears that the T300A risk allele may specifically enhance *Bacteroides* spp.

3\) Data on the basal microbiome are not provided in quiescent \"control\" state given that T300A mice do not spontaneously develop intestinal inflammation.

4\) In Figure 2, concise data indicate stability of microbiome diversity and changes in control and mutant mice, as dictated by human donor stool status. It is unclear why the healthy volunteer is in fact genotype heterozygous T300A (AG), when even the intermediate phenotype appears to impact the microbiome? Could this be addressed?

5\) In Figure 3, the authors show increase in *Bacteroides* in T300A mice that received stool from active Crohn disease, and there are little changes noted in mice receiving stool from active UC patient. Test samples are from small numbers (n=1) of patients, as alluded to by authors.

6\) Interestingly, T300A selectively appears to impact gut T cell populations in mice receiving Crohn disease stool (Figure 4) albeit there is no disease induction. In all mice, stool from all sources appears to increase T cells, relative to germ free mice but there are no RORγt T cells increments. There is no substantive colitis induced by donor stool transfer in the experiments reported --Figure 6---figure supplement 3.

7\) Patient genotype data and stool microbiome data available from Jostins et al. in ref. 7, suggest that T300A in humans conveys a trend to increase *Bacteroides* fragilis, but not robustly with respect to the genus *Bacteroides* and not in a generally significant manner. (Figure 5). The authors suggest that T300A seems to reconfigure the human microbiota and importantly even the presence of a heterozygous genotype displays an intermediate phenotype with respect to *Bacteroides* species.

This current work has certain limitations as noted above, but is an important step as it provides insight into disease subtypes and has identified dysbiosis linked to genetics, which may impact future treatment avenues for IBD patients as well as informing diagnostic tests.

*Reviewer \#2:*

The study by Lavoie et al. explores the interaction between host genetics and the microbiome in inflammatory bowel disease using gnotobiotic T300A mice transplanted with genotyped IBD patient fecal material. Conceptually, this is an important area of investigation as previous studies focused primarily on either the microbial communities of IBD patients, or the role of host genes in modulating SPF microbiota in ATG16L1-deficient or T300A mice. The strength with this study is in combining the relevant microbiome samples (T300A CD vs healthy) in a relevant mouse model (T300A knockin mice) -- however, several key details are still unresolved:

Major points include:

1\) After 7 days of DSS, followed by 7 days of water is there a difference in weight loss or rebound kinetics between WT and T300A mice? Microbiome analysis pre-DSS colitis would be helpful to support the data in Figure 1, and can be provided as supplemental material.

The differences in microbial communities during inflammation between WT vs T300A mice are intriguing. However, during steady-state (no DSS) conditions, how do the microbiome compare? Are the differences observed during DSS colitis also present during naïve conditions? Is the bloom in *Bacteroides* due to DSS and inflammation? The authors state that these \"changes occur before the onset of disease, suggesting that ATG16L1 T300A may contribute initially to dysbiosis \[...\]\" -- if this is the case, do you observe increased *Bacteroides* before DSS colitis induction?

This is important since the following figure (Figure 2) show distinct communities between WT vs T300A recipient mice upon transplantation with CD active microbiota, conceivably in an inflammatory setting analogous to DSS conditions of Figure 1.

2\) Along the same lines, do you observe an enrichment of *Bacteroides* spp. in CD active donor samples (in T300A or WT recipients) vs. CD inactive donor samples? The UC controls are informative, but how does CD active compare to CD inactive in respects to *Bacteroides* abundance?

3\) The donors from healthy control and CD patients were nicely controlled, with all donors with T300A genotype. Were any experiments performed with T300 donors (healthy/CD active/CD inactive)? If so, how do they compare in the analysis in PCA plots (Figure 2A)? It appears that host genotype (T300A) of donor alone is not sufficient drive changes in the composition of the microbiota, as both WT and T300A mice cluster closely together when colonized with active UC T300A donors but not active CD T300A donors (Figure 2B).

Additionally, the authors note that \"the differences in the active CD microbiota in mice are due to the presence of the risk allele T300A as opposed to microbial population drift due to human stool transfer into mice alone\" -- if this is the case, would the authors predict that T300 donors with active CD result in no differences when transplanted into WT and T300A recipient mice? This control would also be relevant when examining *Bacteroides* abundance to support the claim that \"T300A has the potential to drive increases in *Bacteroides* spp.\". Perhaps the authors can refer to the data in Figure 5, and look at animals colonized with WT or Het to compare with T300A samples.

4\) In Figure 2B, how does the microbiome of WT and T300A recipients (CD or UC) compare to the initial donor sample? Is there more drift in one genotype vs. the other?

5\) In Figure 3, is the \"enrichment\" of *Bacteroides* in T300A mice with active CD microbiota truly due to T300A genotype driving the increase in *Bacteroides*? It\'s not clear if the abundance is relative or absolute, and can be compared with the Active UC donors, which appears to be at the same level as T300A Active CD mice. If so, are WT mice with active CD better able to control *Bacteroides* abundance?

*Reviewer \#3:*

Lavoie et al. investigate the contribution of germline variation in the core autophagy gene Atg16L1 (Thr300Ala) to intestinal dysbiosis in murine models. This approach reveals how variants significantly associated with inflammatory bowel disease can impact the microbiome even in the absence of overt disease pathology. Overall, the study is a thorough description of the changes that occur in the T300A mice, both at the level of flora and T cell phenotypes. While the datasets detailing microbial dysbiosis is novel and compelling, the study remains incomplete in a few aspects (detailed below, by Figure). Addressing these would significantly elevate the impact of the manuscript while furthering our understanding of how the T300A genotype impacts intestinal immune cell make-up. It would also provide the level of insight necessary for publication in *eLife*. The suggestions listed attempt to be mindful of the scope and resources within the current article.

Major comments:

Figure 1:

-- Analysis of microbial diversity in animal studies is complex and requires thorough description of the approach used. While the figure and legend provide some level of detail, it would be useful to more clearly state if animals were gender matched, if there was a gender bias observed.

-- Why did authors use 3 mice in WT group that were not cage matched to T300A mutants. (Figure 1A)? The Z-scores (and dendograms) may be driven by these 3 controls that are not ideal for a 16S sequencing study. Do the associations remain if only co-housed mice are re-analyzed?

-- Given the strong association of the T300A variant with ileal Crohn\'s disease, why was ileal \"fecal\" content not assessed in this study? An attempt to perform this analysis, or a clear rationale as to why it wasn\'t attempted would benefit the reader.

Figure 2:

-- Details regarding co-housing and gender(s) used, along with any gender bias if observed, would benefit the reader again. Were all recipients co-housed (either in pairs or other protocols) throughout the study?

Figure 4:

-- What are the baseline alterations in gut immune cell populations in conventionally co-housed WT vs. T300A mice (from Figure 1)?

-- Is the impact on Th1/Th17 abundance cell autonomous? Would adoptive transfer of T300A T cells into a WT recipient reproduce this phenotype? If not, it is an interesting observation as well since it would implicate additional host factors in driving T cell polarization.

-- Authors only assessed specific T cell subsets, while the T300A genotype is germline. How does the T300A genotype impact abundance and/or function of other immune cell subsets relevant to IBD? Presenting data on Treg, NK/NKT, gdTcells or other tissue resident T cells, macrophage/monocyte, dendritic cell and B cell populations would be highly relevant.

-- Given the expansion of RORc^+^ CD4^+^ T cells in the ileum lamina propria, are IL-23 producing DCs or myeloid cells overabundant? A simple measurement of IL12/23 family cytokines from intestinal explants in this study may provide the answer.

Figure 5:

-- A discussion on how the observed dysbiosis may reflect on ileal flora would be useful here, given that the T300A variant is strongly associated with ileal CD.

10.7554/eLife.39982.034

Author response

\[Editors\' note: the authors' plan for revisions was approved and the authors made a formal revised submission.\]

> As you will see, there is consensus among the reviewers that the conclusions of the manuscript, if valid, are of great interest to the field and appropriate for publication in eLife. The reviewers and the Reviewing Editor all agree that the strength of the manuscript is the approach, where human IBD specimens are transferred into germ-free mice to reveal new gene-microbiome interactions. However, the absence of certain information, conditions, and controls calls into question the conclusions. The reason why certain data is missing in this study is likely due to the technically challenging and time consuming nature of this powerful approach. The reviewers are sympathetic to this challenge, and wish to give the authors an opportunity to respond. The following appear to be the big picture consensus concerns:
>
> 1\) Analysis of the microbiome composition pre-DSS (or no DSS) is necessary to interpret the findings post-DSS.

We agree with the reviewers' concerns and think this is an important control missing from the work provided upon initial submission. We have analyzed stool samples by 16S rRNA gene amplicon sequencing from conventionally-housed, specific pathogen free (SPF) WT and T300A knockin mice under steady state conditions without DSS treatment. These data are now found in Figure 1. We can confirm from our data (histology -- colitis scores of zero from the colons of SPF T300A mice) that these mice do not present with colitis under these conditions.

> 2\) The rationale for donor selection is unclear and potentially problematic. The non-T300A donors may be key to interpretation of the experiments and establishing baseline. Similarly, the T300A genotype does not appear to have a contribution towards microbiome composition in UC, although we cannot say that for sure with the current analysis. It is unclear mechanistically why it matters whether the sample is from UC vs CD with the same genotype. Also, why is the healthy control heterozygous for T300A? A related issue is the low N number for human donors. These differences between conditions (health status and genotype) may be a reflection of random donor heterogeneity.

To address these concerns, we analyzed sequencing data from T300A mice associated with stool from a patient with inactiveCrohn's disease and without a mutation in the *ATG16L1* gene which we include in the re-submission. These data are found in Figure 3.

Indeed, the composition of the microbiota can vary from person to person and within an individual with IBD during a flare and in remission.

The availability of donor human stool that was collected at clinic and immediately flash frozen was limited. The ideal combinations of appropriately collected sample and individual phenotype and genotype were not available to us.

We have incorporated text into the manuscript that more thoroughly addresses donor selection, sample collection challenges, and sample heterogeneity.

As to why the healthy control is heterozygous for T300A, the guanine to alanine substitution, which converts a threonine to alanine at position 300 in ATG16L1, is a relatively common mutation in healthy individuals. Hampe et al. have shown that the frequency of the G allele is 0.53 in control individuals. We have explained this more clearly and in more detail in the text of the re-submitted manuscript.

> 3\) A more thorough examination of the immune compartment is needed. There is a sense that the authors are finding what they\'re looking for.

We agree that more subsets of T cells as well as myeloid cells can be altered under these conditions and in the context of IBD. We have additional data on Foxp3+ regulatory T cells, Gata3^+^ Th2 cells as well as a variety of myeloid cell subsets including CD11c^+^MHCII^+^ dendritic cells, CD103^+^ "tolerogenic" dendritic cells, CD11b^+^GR-1^+^ neutrophils and inflammatory monocytes from our gnotobiotic association studies that are now included in Figures 6, 7 and 8 in the re-submitted manuscript.

> 4\) Details regarding co-housing, gender, and littermates are missing. Depending on how the experiments were performed, a subset may need to be repeated under appropriate conditions to validate the initial findings.

We provide information on caging, gender, and littermates as requested by the reviewers in Supplementary file 1.

We carried out the following experiments to ameliorate these concerns and significantly enhance the mechanism we present in the manuscript.

We now include experiments that involve associating germ-free (GF) mice and mice with a limited microbiota (Altered Schaedler Flora -- ASF mice) with an individual strain of *Bacteroides ovatus* (ATCC 8483). We completed experiments that involved associating WT and T300A cage-matched, age-matched GF and ASF mice with or without *Bacteroides ovatus*. These data are found in Figure 7 and Figure 8

Data from these experiments address the question of whether T300A mice housed with WT mice show differences in gut immune populations by flow cytometry in the presence of *B. ovatus*. We also analyzed the gut tissue for signs of damage, hyper-proliferation, inflammation and any abnormalities observed on histology-based review of these tissues.

Mechanistically, these experiments reveal the effect of *B. ovatus* alone on the gut immune response. We are focusing on *B. ovatus*, as this species was enriched in T300A mice associated with active Crohn's disease stool, but not in mice associated with stool from patients with active ulcerative colitis in Figure 4 of our manuscript. These findings correlated with increases in Th17 cells in the gut of T300A mice associated with active Crohn's disease stool. As mentioned in the manuscript text, previous studies have shown a potential effect of *Bacteroides spp*. on Th17 populations in the gut. These new studies that are now part of the resubmitted manuscript specifically address whether an isolate from this species alone or in concert with the ASF can alter Th17 frequency in the gut of T300A mice.

Summary of experiments and textual revisions in this re-submission:

Experimental Revisions:

a\) Inclusion of data on donor input microbiome sample, see Figure 3A.

b\) Inclusion of data from DSS experiment, e.g. weight trajectories from T300A and WT mice, see Figure 2E.

c\) Inclusion of pre-DSS microbiome analyses and colitis scores of T300A and WT conventional mice, see Figure 1.

d\) Inclusion of data on flow cytometry profiles from gnotobiotic experiments on Th2, Treg, and myeloid cells subsets, see Figure 6.

*e) B. ovatus* gnotobiotic experiments with lamina propria immune subset profiling, see Figure 7 and Figure 8.

Textual Revisions:

a\) Improved textual explanation of donor selection for gnotobiotic experiments.

b\) Inclusion of metadata from gnotobiotic experiments, e.g. mouse gender and caging.

c\) Fixed typos mentioned by reviewer number 2.

> Reviewer \#1:
>
> \[...\] 1) GWAS studies have linked over 230 genetic risk loci to increased IBD risk but this manuscript addresses only one and even when transferring stool from active Crohn disease patient does not cause experimental colitis per se. Further, already published work has shown that NOD2 variants, which may interact in aberrant manner withATG16L1, predispose to dysbiosis -- see Knights et al., 2014.

Due to the complex nature of IBD and the abundance of SNPs associated with disease, we assert that it is important to look at individual SNPs separately to carry out mechanistic studies aimed out unraveling disease causality.

> 2\) Alterations in mouse fecal microbiota are only noted in in SPF T300A vs. WT mice following on the generation of gut inflammation, as in Figure 1. It appears that the T300A risk allele may specifically enhance Bacteroides spp.
>
> 3\) Data on the basal microbiome are not provided in quiescent \"control\" state given that T300A mice do not spontaneously develop intestinal inflammation.

We have responded to reviewer \#1's comments 2 and 3 in the main response number 1 above.

> 4\) In Figure 2, concise data indicate stability of microbiome diversity and changes in control and mutant mice, as dictated by human donor stool status. It is unclear why the healthy volunteer is in fact genotype heterozygous T300A (AG), when even the intermediate phenotype appears to impact the microbiome? Could this be addressed?
>
> 5\) In Figure 3, the authors show increase in Bacteroides in T300A mice that received stool from active Crohn disease, and there are little changes noted in mice receiving stool from active UC patient. Test samples are from small numbers (n=1) of patients, as alluded to by authors.
>
> 6\) Interestingly, T300A selectively appears to impact gut T cell populations in mice receiving Crohn disease stool (Figure 4) albeit there is no disease induction. In all mice, stool from all sources appears to increase T cells, relative to germ free mice but there are no RORγt T cells increments. There is no substantive colitis induced by donor stool transfer in the experiments reported --Figure 6---figure supplement 3.
>
> 7\) Patient genotype data and stool microbiome data available from Jostins et al. in ref. 7, suggest that T300A in humans conveys a trend to increase Bacteroides fragilis, but not robustly with respect to the genus Bacteroides and not in a generally significant manner. (Figure 5). The authors suggest that T300A seems to reconfigure the human microbiota and importantly even the presence of a heterozygous genotype displays an intermediate phenotype with respect to Bacteroides species.

These comments have been addressed in main response number 2 above and in the text of the manuscript as well.

> Reviewer \#2:
>
> \[...\] 1) After 7 days of DSS, followed by 7 days of water is there a difference in weight loss or rebound kinetics between WT and T300A mice? Microbiome analysis pre-DSS colitis would be helpful to support the data in Figure 1, and can be provided as supplemental material.
>
> The differences in microbial communities during inflammation between WT vs T300A mice are intriguing. However, during steady-state (no DSS) conditions, how do the microbiome compare? Are the differences observed during DSS colitis also present during naïve conditions? Is the bloom in Bacteroides due to DSS and inflammation? The authors state that these \"changes occur before the onset of disease, suggesting that ATG16L1 T300A may contribute initially to dysbiosis \[...\]\" -- if this is the case, do you observe increased Bacteroides before DSS colitis induction?
>
> This is important since the following figure (Figure 2) show distinct communities between WT vs T300A recipient mice upon transplantation with CD active microbiota, conceivably in an inflammatory setting analogous to DSS conditions of Figure 1.

We have addressed reviewer \# 2 concerns in comment 1 in the main response number 1 above.

We include the weight trajectory data for DSS treated mice in the resubmission.

> 2\) Along the same lines, do you observe an enrichment of Bacteroides spp. in CD active donor samples (in T300A or WT recipients) vs. CD inactive donor samples? The UC controls are informative, but how does CD active compare to CD inactive in respects to Bacteroides abundance?
>
> 3\) The donors from healthy control and CD patients were nicely controlled, with all donors with T300A genotype. Were any experiments performed with T300 donors (healthy/CD active/CD inactive)? If so, how do they compare in the analysis in PCA plots (Figure 2A)? It appears that host genotype (T300A) of donor alone is not sufficient drive changes in the composition of the microbiota, as both WT and T300A mice cluster closely together when colonized with active UC T300A donors but not active CD T300A donors (Figure 2B).
>
> Additionally, the authors note that \"the differences in the active CD microbiota in mice are due to the presence of the risk allele T300A as opposed to microbial population drift due to human stool transfer into mice alone\" -- if this is the case, would the authors predict that T300 donors with active CD result in no differences when transplanted into WT and T300A recipient mice? This control would also be relevant when examining Bacteroides abundance to support the claim that \"T300A has the potential to drive increases in Bacteroides spp.\". Perhaps the authors can refer to the data in Figure 5, and look at animals colonized with WT or Het to compare with T300A samples.

We have noted that we included information regarding association of T300A mice with stool from a patient with inactive CD and a WT genotype.

> 4\) In Figure 2B, how does the microbiome of WT and T300A recipients (CD or UC) compare to the initial donor sample? Is there more drift in one genotype vs. the other?

We have 16S rRNA gene amplicon data on human stool samples pre-association that are included in the re-submitted manuscript.

> Reviewer \#3:
>
> \[...\] Figure 1:
>
> -- Analysis of microbial diversity in animal studies is complex and requires thorough description of the approach used. While the figure and legend provide some level of detail, it would be useful to more clearly state if animals were gender matched, if there was a gender bias observed.

We provide information on gender in our analysis. We find this topic compelling and in these experiments we did not find differences related to gender in the mice.

> -- Given the strong association of the T300A variant with ileal Crohn\'s disease, why was ileal \"fecal\" content not assessed in this study? An attempt to perform this analysis, or a clear rationale as to why it wasn\'t attempted would benefit the reader.

We think that because human stool samples are collected as passed fecal samples and not ileal samples, we wanted to remain consistent with how these human samples were collected when we conducted our mouse microbiota studies.

> Figure 2:
>
> -- Details regarding co-housing and gender(s) used, along with any gender bias if observed, would benefit the reader again. Were all recipients co-housed (either in pairs or other protocols) throughout the study?

This comment has been addressed in the main response number 4 above.

> Figure 4:
>
> -- What are the baseline alterations in gut immune cell populations in conventionally co-housed WT vs. T300A mice (from Figure 1)?
>
> -- Is the impact on Th1/Th17 abundance cell autonomous? Would adoptive transfer of T300A T cells into a WT recipient reproduce this phenotype? If not, it is an interesting observation as well since it would implicate additional host factors in driving T cell polarization.

We think that these experiments, while important, cannot be completed in a two month time frame.

> -- Authors only assessed specific T cell subsets, while the T300A genotype is germline. How does the T300A genotype impact abundance and/or function of other immune cell subsets relevant to IBD? Presenting data on Treg, NK/NKT, gdTcells or other tissue resident T cells, macrophage/monocyte, dendritic cell and B cell populations would be highly relevant.

We have addressed this with additional data mentioned in the main response number 3 above.

> -- Given the expansion of RORc^+^ CD4^+^ T cells in the ileum lamina propria, are IL-23 producing DCs or myeloid cells overabundant? A simple measurement of IL12/23 family cytokines from intestinal explants in this study may provide the answer.
>
> Figure 5:
>
> -- A discussion on how the observed dysbiosis may reflect on ileal flora would be useful here, given that the T300A variant is strongly associated with ileal CD.

We did not collect data on IL-23 or collect ileal contents. However, we provide data on Il-23 transcript levels from the lamina propria of the colon and ileum in Figure 9 wherein we show data demonstrating increased expression of *Il23p19* in lamina propria from the colon and ileum of T300A ASF mice associated with *Bacteroides ovatus* 8483.

[^1]: These authors contributed equally to this work.
